Dexcom, Inc., a global leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, announced that Health Canada has approved the next-generation Dexcom G7 Continuous Glucose Monitoring System for people with all types of diabetes, ages two years and older. Diabetes is a complex and burdensome condition affecting more than 3 million Canadians. It requires around-the-clock management of glucose levels and daily treatment decisions to manage the disease. Health Canada approval of Dexcom G7 gives Canadians access to a game changing technology that makes managing diabetes easier, and has been shown to reduce hospitalizations and emergency room visits due to hypoglycaemia by up to 42 per cent.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!